Meet with our product experts in one-on-one virtual sessions
Set Up a Meeting
Our Sustainability and ESG Goals
Dr. Reddy's integrated annual and sustainability report for the Fiscal Year 2024 is out. This edition acknowledges 40 years of Dr. Reddy's by taking you through our most significant milestones.
Our purpose "Good health can't wait" translates into three pillars with sustainability at the core
Our progress was recognized in our ascent to the Dow Jones Sustainability World Index, improved position in the S&P global sustainability yearbook, and gold medal status by Eco Vadis.
Sustainability is deeply embedded in our purpose and forms the core of our organization.
Our journey began with APIs in 1984, and we evolved from small molecules to large molecules and from APIs to finished formulations over the decades. Amidst this evolution, what has remained constant at the heart of our organization is a deep commitment to patients and the customers we serve through our core principles of collaboration and sustainability.
By the end of FY2024, we had served over 700 million patients and continue our endeavours to reach over 1.5 billion patients globally by 2030. This means almost one in every five people on this planet will use Dr. Reddy’s product or service. The health of people is strongly linked to the health of our planet. That's why our integrated report also shows how sustainability and business are strongly linked.
Our Sustainability Goals
Being committed to environmental stewardship
- Reducing carbon emissions
- 100% renewable power by 2030
- Carbon neutrality in our direct operations (Scope 1 & Scope 2) by 2030
- 12.5% reduction in indirect carbon emissions across our supply chain (Scope 3 emissions) by 2030
- Water positivity
- Be water positive by 2025.
Making our products accessible and affordable for patients
- Access
- Serve 1.5 billion patients by 2030.
- Affordability
- 25% of our new-launches to be first-to-market by 2027.
- Innovation
- 3 innovative solutions to improve the standard of treatment every year from 2027.
Contributing to a fairer and more socially inclusive world
- Equity, diversity, and inclusion
- At least 35% women in senior leadership by 2030
- Gender parity by 2035
- Include at least 3% persons with disabilities (PwD) in our workforce by 2030.
- 100% living wages for our on-premises extended workforce by 2025.
Enhancing trust with our stakeholders
- Highest standards of compliance
- Meet the highest standards on compliance and ethics backed by robust corporate governance ESG disclosures.
- ESG Disclosures: Progressively enhance disclosure on our ESG progress to reach top quartile by 2025.
- Strategic Suppliers: 100% strategic suppliers to be compliant with our ESG framework by 2030.
- ESG disclosures
- Strategic suppliers
What we achieved in the past year:
Active Pharmaceuticals Ingredients (APIs)
ESG in the pharmaceutical industry is an essential prerequisite. In our core API business, our focus on innovation-led affordability gives our customers access to the most complex active ingredients while maintaining a consistent global quality standard. In addition, our partnerships with leading generic formulation brands to fulfil their drug development needs have also given an edge to our own generics business, enabling us to deliver higher quality at competitive costs.
We are present across multiple channels, with customer engagements along different points in the development and manufacturing value chain—from discovery and CDMO (Contract Development and Manufacturing Organization) services to development, manufacture, and sales. Through integrated discovery and CDMO services, we have executed more than 500 projects over 20 years.
Highlights for the year
API (Develop, manufacture, and sell APIs to customers globally)
- 225+ active drug master files (DMFs).
- 55+ products in pipeline.
- 139 DMFs filed in FY 2022.
API+ (Institutional and B2B sales of value-added offerings above the API)
- Currently in 25+ countries
Our Community Initiatives
Education
- Enhance the quality of education and provide equal learning opportunities to the children from the marginalised communities through:
- Kallam Anji Reddy Vidyalaya and Junior Vocational College
- School Improvement Programme (SIP)
- Sashakt scholarship for girls
Livelihood
- Provide skills to youth for enhancing their employability and to enhance livelihoods by extending support to small and marginal farmers through:
- Placement linked skilling programme for youths and Persons with Disability
- Healthcare Skilling in the non – medical healthcare sector
- Agriculture programme focusing on capacity and income enhancement of small and marginalised farmers.
Health
- Making healthcare accessible and affordable and reliable for the communities through:
- Rural healthcare services at the doorstep through Community Health Intervention Program
- Tele-counselling support for mental health through the Roshni Helpline
- Include at least 3% persons with disabilities (PwD) in our workforce by 2030.
- Improving primary healthcare services to improve the quality of primary care services in the selected Primary Healthcare Centres
Environmental Sustainability
Promoting sustainable agriculture practices and wildlife conservation through:
- Climate Smart Agriculture and Regenerative Agriculture practices
- Conserving Tigers and their habitat in the Eastern Ghats. Read More
Sustainability in the pharma industry is a vital aspect. Our strength in innovation, ethical values, and focus on bringing critical, life-saving products early to market secures a unique kind of sustainability for us. In addition, our leadership across global markets indicates our strong alignment with our & Good Health Can’t Wait agenda.
Pharmaceutical companies’ sustainability is an increasingly important topic for the entire world. While we renewed our goals in 2023 to adapt to changing stakeholder expectations, address climate change, and our resolve to work on material issues, we continued to examine more ways to make an impact. We consulted a more extensive set of global pharmaceutical sustainability and pharmaceutical standards and frameworks, and these findings guided our ESG reviews with the leadership and Board.
Combining a top-down and bottom-up approach, using more tools such as our updated enterprise risk management findings, we set 14 bold and ambitious goals across the ESG dimensions to form our vision for 2030. Each of these goals considers our critical material topics, the external environment in which we operate, and the business and social impact we can create. Read Less
Our Sustainability Framework
At Dr. Reddy’s, we are committed to taking meaningful action for a sustainable future. With our long-standing commitment to protecting the environment, we are working on solutions that help minimize the impact of our operations, driving improvements in multiple areas at various stages of the product life cycle. Read More
Looking at issues of maximum importance to our stakeholders and the business, we are in the process of identifying material issues and building our strategic sustainability framework. We will develop ambitious goals and management targets for each focus area, with multiple milestones, incorporating governance systems and processes, monitoring, and disclosing our performance for each goal, and ensuring independent third-party assurance.
We are determined to play our part in upholding the more prominent global perspective and sustainable development in pharmaceutical industry. We will align ourselves with the United Nations sustainable development goals (UN SDGs), mapping them with our top material issues, allocating internal resources, taking relevant actions, and building technical capabilities. We are also working on greater integration of ESG into our business and building stronger stakeholder relationships by intensifying dialogue and communicating our vision and progress around material issues.
We are determined to play our part in upholding the more prominent global perspective. We will align ourselves with the United Nations' sustainable development goals (UN SDGs), mapping them with our top material issues, allocating internal resources, taking relevant actions, and building technical capabilities. We are also working on greater integration of ESG into our business and building stronger stakeholder relationships by intensifying dialogue and communicating our vision and progress around material issues.
The ESG principles underlie our business strategy. We address customer needs and create value for all stakeholders by addressing unmet needs. We are conscious of our footprint and impact and believe that addressing sustainability challenges is the need of the hour. Therefore, we continue to follow the best practices to make our business more sustainable. Read Less
R&D Operations Guided by Sustainability Framework
Since 2010, Dr. Reddy’s has been committed to the UN Global compact corporate responsibility initiative and its principles in the environment, sustainability, and green chemistry. As an active pharmaceutical ingredient supplier, our primary goal is to develop products that will provide a reliable supply of products of superior quality for the pharmaceutical industry. Also, we ensure that our APIs are produced using eco-friendly processes so that our customers can sustainably access our APIs.
Robust Supply chain
Our supply chain process is based on a strategic model to ensure a practical, reliable, and sustainable supply of goods and services based on a segmented operation. A scorecard is generated for all the KPIs, and we monitor the progress toward each goal. In addition, a well-defined Supplier Code of Conduct (SCOC) governs our supply chain management. We also have a dedicated SCM (Supply Chain Management) team that addresses all sustainable sourcing elements with special emphasis on supply continuity, quality and compliance, supplier relationships, capacity and capability building, supplier, and performance management, and aligning the partners with our vision of sustainability.Read More
- Strong partner network - Intelligence to get early alerts on issues, enabling us to take corrective actions.
- Cross-industry collaboration groups - Support groups of transporters, shippers, airlines, etc. came together for information sharing and solutions.
- We are opening ourselves to new possibilities - Adopting new solutions such as moving cold chain products by road and sea, expanding our logistics footprint to new ports and airports, introducing new origin and destination pairs, and exploring digital technology (e.g., digital signatures for regulatory documents).Read Less
"Sustainability is at the core of our mission at Dr. Reddy’s. We are committed to minimizing our environmental footprint, empowering communities, and ensuring ethical business practices. Together, we can build a healthier planet for future generations".
Deepak Sapra,
CEO, Pharmaceutical Services & Active Ingredients.
Disclaimer
No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.